This flexibility, combined with access to alternative peptides like tirzepatide when semaglutide reaches a plateau, gives you pathways forward that Wegovy alone cannot provide
The peptides mechanism of action involves reducing food intake, increasing energy expenditure, and potentially stimulating hepatic fatty acid oxidation while reducing hepatic lipogenesis
Husni, A., Jeon, J
Yes, with the right (emphasis on right) support in place
Like GLP-1s, they have been touted by wealthy, high-profile figures, including Gwyneth Paltrow, Joe Rogan, and Health Secretary Robert F
GLP-1 agonists are promising for MASH treatment because they target multiple aspects of the disease, including fat accumulation, inflammation, and insulin resistance, which are all key factors in MASH progression